Table 4: Median PFS and 95% confidential intervals within CMS subtypes and low and high IPS subgroups in various populations received different therapeutics.

 

RAS wild type treated with cetuximab n = 94

RAS wild type treated with bevacizumab n = 43

RAS wild type treated with chemotherapy alone n = 51

 

mPFS (95% CI)

P

mPFS (95% CI)

P

mPFS (95% CI)

P

CMS1/3/4

5.033 (3.092-6.975)

0.060

7.033 (4.153-9.914)

0.319

9.133 (4.106-14.160)

0.596

CMS2

9.767 (5.944-9.989)

11.567 (10.055-13.078)

10.267 (4.460-16.074)

Low IPS

5.333 (2.629-8.038)

0.004

8.333 (6.863-9.803)

0.767

21.000 (0.000-43.888)

0.413

High IPS

8.033 (6.055-10.012)

10.533 (9.032-12.035)

9.133 (6.712-11.554)